Moderna Inc. announced Tuesday that its vaccine for respiratory syncytial virus (RSV) in adults over 60 years old is 84% effective at preventing lower respiratory tract diseases.
Based on the results, the Cambridge company plans to submit the vaccine for approval by July at the latest.
More on this story from Boston Business Journal
Get Boston local news, weather forecasts, lifestyle and entertainment stories to your inbox. Sign up for NBC Boston’s newsletters.
Copyright Boston Business Journal
